Thermo Fisher Scientific Inc
Latest Thermo Fisher Scientific Inc News and Updates
Materials Sector Stocks Weigh Market Down, Might Be Time to Buy
Microsoft Infiltrates the Mobile App Space: The Xamarin Acquisition
On February 24, Microsoft announced that it will acquire Xamarin, a mobile app platform provider. Financial details of the deal were not disclosed.
What Analysts Recommend for Accelerate Diagnostics and Peers
Of the four analysts covering Accelerate Diagnostics in January 2018, three analysts have given the stock a “buy” rating.
What Are Leon Cooperman’s Top Holdings?
In Q3, billionaire investor Leon Cooperman’s top five holdings were Fiserv, Alphabet, United Continental, Chimera Investment, and Cigna.
How Hologic’s Valuation Stacks Up with Peers
The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.
Analysts Raise Target Prices on ABT ahead of Q3 Earnings
Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.
How Tax Reform Affected Medtronic’s 3Q18 Performance
Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]
A Look at Hologic Stock’s Recent Performance
Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.
How Are Stryker’s Core Strategies Working Toward Its Growth?
Stryker (SYK) registered strong 3Q16 earnings on October 27, 2016. The company’s reported earnings exceeded analysts’ estimates.
BD’s Stock Price Performance after Recent 52-Week High
On December 28, Becton, Dickinson and Company (BDX), or BD, closed trading on the day at $214.32 per share. Currently, BD stock’s 50-day moving average stands at $221.22.
How Has Boston Scientific Stock Performed Recently?
Boston Scientific (BSX) was trading at $27.9 on June 29, 2017.
This Could Be a Solid Growth Driver for Myriad Genetics in 2018
Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.
Why is leverage a double-edged sword for companies like Apple?
Corporate bond issuance in the U.S. reached $1.4 trillion in 2013, according to the Securities Industry and Financial Markets Association (SIFMA), a new record.
Illumina Stock Continues Its Bull Run
Illumina (ILMN) reached a 52-week high of $357.93 per share on August 31.
How Stryker’s Margins Are Driven by Its CTG Program
Cost transformation for growth (or CTG) is Stryker’s program that focuses on driving leveraged growth by structural cost optimization.
Thermo Fisher Scientific’s Gross Margin Trends
In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.
Analysts Remain Bullish on Illumina Stock
In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.
Understanding Illumina’s Gross Margin Trend
Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.
Understanding Illumina’s Geographical Performance
For 2018 and 2019, Illumina is expected to generate revenues of $3.33 billion and $3.80 billion, respectively.
Thermo Fisher Beats Analysts’ Estimates in Q3 2018 Earnings
Thermo Fisher Scientific (TMO) reported its third-quarter results today. It surpassed analysts’ estimates for EPS and revenue.
Thermo Fisher’s Third-Quarter Revenue Estimates
The Life Sciences Solutions segment, including reagents, instruments, and consumables, contributes ~25% of Thermo Fisher’s total revenues.
What to Expect from Thermo Fisher’s Third-Quarter Earnings
Thermo Fisher Scientific (TMO), a leading life sciences company, is scheduled to release its third-quarter earnings on October 24.
Edwards Lifesciences’ Q3 2018 Earnings Estimates
Edwards Lifesciences is expected to register third-quarter adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.
What to Expect of Edwards Lifesciences’ Q3 2018 Sales
Wall Street expects Edwards Lifesciences to register sales of $0.93 billion in the third quarter, representing a YoY (year-over-year) rise of 10.8%.
What ResMed’s Valuation Trend Indicates
The mean rating for ResMed (RMD) stock is 2.6, and its target price is $104.69.
What’s the Upside Potential for Agilent Technologies Stock?
In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018.
What Waters Corporation’s Valuation Trend Indicates
In September, of the 15 analysts covering Waters Corporation (WAT) stock, ten have given it “holds.”
Is Abbott Laboratories Trading at a High Valuation in September?
Abbott stock has been gaining momentum recently, and its valuation has improved.
How Quest Diagnostics Is Positioned in 2018
Quest Diagnostics generated revenues of $1.92 billion in the second quarter of 2018 as compared with $1.86 billion in the second quarter of 2017.
What’s Driving the Growth in Thermo Fisher Scientific’s Segments?
Thermo Fisher Scientific (TMO) operates in four business segments.
Cynosure Headwinds Trigger Analyst Downgrades on HOLX Stock
As of September 18, ten of the 19 analysts that cover HOLX stock gave the company a “buy” or “strong buy” recommendation.
Thermo Fisher to Offer Complete Cannabis Testing Solutions
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.
How Thermo Fisher Scientific’s Valuation Looks in September
Thermo Fisher Scientific currently trades at a forward PE multiple of ~19.9x.
How BD Stock Has Performed in the Last Year
On February 6, 2018, BD released its 1Q18 earnings results, which came in ahead of expectations.
Analyst Ratings for Thermo Fisher Scientific before 4Q17 Results
Thermo Fisher Scientific (TMO) will announce its 4Q17 and fiscal 2017 results on January 31, 2018. It has launched some innovative products and entered into strategic collaborations and partnerships.
What Are Accelerate Diagnostics’ Key Strengths?
In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock.
Does Accelerate Diagnostics’ Financial Performance Bode Well?
The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17.
Baxter International Expected to Post Strong 4Q17 Results
Earnings results Baxter International (BAX) is expected to announce its 4Q17 and fiscal 2017 earnings results on or around January 30, 2018. The company announced stellar 3Q17 earnings results on October 25, 2017. Year-over-year, Baxter International expects to report 4Q17 sales growth of 4%–5% and constant-currency sales growth of ~2%. However, the company’s operational sales growth, expected […]
A Look at Thermo Fisher Scientific’s Recent Stock Price Performance
TMO stock reported its 52-week high of $201.20 on October 26, 2017, when the company released its 3Q17 earnings results.
TMO’s Acquisition from EPTEK Technology Could Boost Its China Opportunity
On December 4, 2017, Thermo Fisher Scientific (TMO) completed the acquisition of some assets from EPTEK Technology and related entities that have offices in mainland China and Taiwan.
Thermo Fisher Scientific’s Deepening Ties with Sema4
Thermo Fisher Scientific’s (TMO) Core Informatics’ Platform for Science’s modules, including a LIMS (laboratory information management system), could soon be implemented at Sema4’s two major laboratory facilities.
TMO’s Launch of New Research Assay for Cancer
On December 7, 2017, Thermo Fisher Scientific announced the launch of a new targeted NGS (next-generation sequencing) research panel.
Thermo Fisher Expands Its Partnership with Genome Diagnostics
In December 2017, Thermo Fisher Scientific (TMO) expanded its partnership with Genome Diagnostics (or GenDx), a Netherlands-based firm offering molecular diagnostics solutions.
What’s Driving BD’s Operating Margin Expansion
Overview BD (BDX) has registered strong operating margin expansion in recent years. Its margin improved by 100 basis points in fiscal 2015 and 200 basis points in fiscal 2016. In fiscal 2017, BD’s margin expanded by ~180 basis points. In 4Q17, BD’s operating margin grew ~14.6% YoY (year-over-year), limited by 700 basis points due to the divestiture of BD’s […]
Understanding Abbott’s Alere Acquisition: What We Can Expect
On October 3, 2017, Abbott announced the completion of its acquisition of Alere, which has had troubles since the initial announcement in February 2016.
Baxter International’s Latest Guidance for Fiscal 2017
Baxter International’s sales growth guidance for fiscal 2017 is expected to be ~4% on a reported basis.
Understanding BD’s Recent Stock Performance
BD has a 50-day moving average of $197.25, while its 200-day moving average is $192.35.
Latest Product Launch Expands BD’s Genomics Portfolio
Becton Dickinson accelerated its strategy to establish itself as the leader in single cell genomics with its recent launch of BD Rhapsody, a single cell analysis platform.
Inside Baxter International’s Stock Price Performance
On September 7, 2017, BAX stock closed at $62.84 per share. It has a 50-day moving average of $61.15 and a 200-day moving average of $57.14.
Taking a Look at Stryker’s Recent Stock Price Performance
On August 31, Stryker (SYK) closed trading at a closing price of $139.3. It has a 50-day moving average of $144.7 and a 200-day moving average of $137.5.
Which Way Are Zimmer Biomet’s Analysts Leaning after 2Q17?
Of the 29 brokerage firms tracking Zimmer Biomet, 18 (62%) analysts gave ZBH stock a “buy” rating, while nine (~31%) provided a “hold” rating.
How Is Becton Dickinson Progressing with Emerging Market Growth?
Becton Dickinson’s (BDX) emerging markets registered a strong double-digit growth of 10.9% in 3Q17.
What Investors Can Expect from Medtronic’s Fiscal 1Q18 Results
In fiscal 4Q17, Medtronic’s revenue came in at $7.9 billion, representing YoY (year-over-year) growth of ~5%.
Key Highlights of Varian Medical Systems’ Fiscal 2Q17 Earnings
On April 26, 2016, Varian Medical Systems (VAR) released its 2Q17 earnings. VAR beat consensus estimates for revenues in 2Q17 by ~0.8% and reported in-line earnings per share.
How Thermo Fisher Scientific’s Stock Has Performed
Thermo Fisher Scientific (TMO) closed trading at $175.3 on July 27, 2017.
Stryker Exceeded Analysts’ Sales Estimates in 2Q17
On July 27, 2017, Stryker (SYK) released its 2Q17 earnings. The company reported strong earnings and exceeded analysts’ expectations.
Thermo Fisher Scientific Accelerates Its Semiconductor Sequencing
On June 29, 2017, Thermo Fisher Scientific (TMO) announced the addition of three new products to its semiconductor failure analysis workflows portfolio.
Most Analysts Recommend ‘Buys’ on Thermo Fisher Scientific
In a recent Reuters survey of 17 brokerage companies, Thermo Fisher Scientific received “buy” ratings from ~88% of analysts, while ~12% gave it “hold” ratings.
Varian Medical Systems: Analyzing Its Stock Performance
Varian Medical Systems (VAR) was trading at $102.7 on June 29, 2017. It has a 50-day moving average of $100.4 and a 200-day moving average of $88.8.
FDA Warning Letter to Zimmer Biomet Resolved, Boosts Confidence
On June 13, 2017, Zimmer Biomet (ZBH) announced that the FDA warning letter issued in June 2015 relating to its Zhejiang manufacturing facility in China has been closed.
Behind Thermo Fisher’s Recent Stock Performance
TMO stock was trading at $173.2 on May 30, 2017. The stock had a 50-day moving average of $165.9 and a 200-day moving average of $153.8 that day.
How Zimmer Biomet Stock Has Performed Recently
Zimmer Biomet Holdings (ZBH) was trading at $118.40 on May 30, 2017. It has a 50-day moving average of $119.70 and a 200-day moving average of $114.20.
Understanding Thermo Fisher’s Capital Deployment Strategy
Thermo Fisher Scientific expects to deploy 60%–75% of its capital toward M&As (mergers and acquisitions).
Understanding Thermo Fisher’s Growth Strategy
Thermo Fisher Scientific (TMO) has always focused on innovation as a key growth strategy.
How Long Can Thermo Fisher Scientific’s Asia-Pacific Growth Momentum Last?
Thermo Fisher Scientific (TMO) has a presence around the globe, but around 80% of its revenues are generated from developed markets.
Abbott Is Expected to Report a Modest Rise in Net Profit Margins
Abbott Laboratories (ABT) has projected its 2017 gross margin to be ~60%, higher than the 57.3% it reported in 2016.
Abbott Laboratories Still Dominates the Medical Device Segment
In 2017, Abbott Laboratories (ABT) plans to focus on the integration of St. Jude Medical’s medical device business, realizing deal synergies, and achieving financial targets.
What Bio-Rad Laboratories Expects from Life Science
In 1Q17, Bio-Rad Laboratories’ (BIO) Life Science segment reported revenues of ~$174.3 million, which represents a YoY rise of ~5.1%.
Inside Bio-Rad Laboratories’ Robust Revenue Growth Projection for 2017
On March 13, 2017, Bio-Rad Laboratories (BIO) provided a long-term, currency-neutral revenue growth target of around 3%–5%.
Bio-Rad Laboratories on the Street: Analysts’ Recommendations in May
In 1Q17, Bio-Rad Laboratories (BIO) reported revenues of ~$500.1 million, which represented a YoY (year-over-year) rise of around 6.1%.
Trump Trade Fades amid Political Debacle: What’s the Impact?
As part of Obamacare, a medical device tax of 2.3% has been implemented on medical device companies in the United States.
What Analysts Recommend for Stryker after 1Q17 Results
The consensus 12-month target price for Stryker is $141, a ~3.5% return potential.
How ZBH Stock Has Performed Recently
Zimmer Biomet Holdings (ZBH) was trading at $123.3 as of April 24, 2017.
Why Zimmer Biomet Could See Revenue Growth in 1Q17
Wall Street analysts expect Zimmer Biomet’s 1Q17 revenue to be about $1.96 billion, a ~3% increase on a YoY (year-over-year) basis.
Behind JNJ’s Medical Devices Growth Trajectory
In 1Q17, Johnson & Johnson’s (JNJ) Medical Device segment revenues came in at ~$6.3 billion, as compared to $6.1 billion in 1Q16.
BD Lifesciences’s Product Pipeline Could Boost Its Fiscal 2017 Growth
Becton, Dickinson and Company (BDX) recently launched BD Barricor and BD Ultra Touch Push Button under its Pre-Analytical Systems division.
Becton Dickinson’s Long-Term Growth Profile and Expectations
After executing its growth strategies during the last five years, Becton, Dickinson and Company (BDX) has achieved its targeted growth rates of 5% top-line organic growth and 10% bottom-line growth.
How Is Thermo Fisher Scientific’s FEI Integration Process Going?
Thermo Fisher Scientific (TMO) completed the acquisition of FEI Company on September 19, 2016.
Exploring the Nuances of Stryker’s Cost Transformation for Growth
Cost transformation growth is one of Stryker’s key strategies for driving growth. The company has come a long way from its decentralized structure prior to 2010.
How Will the US Election’s Results Impact Stryker’s Business?
Stryker (SYK) believes that the election of Donald Trump as the new US president could be good news for the US medical device industry.
What Are Analysts’ Latest Recommendations for Stryker?
In a Reuters survey of 26 brokerage companies on November 18, 2016, about 61.5% of analysts rated it as a “buy,” and 30.8% rated it as a “hold.”
How Did Stryker’s Stock Perform after Its 3Q Earnings Release?
Stryker (SYK) was trading at $114.30 on October 28, 2016, with a 50-day moving average of $114.70 and a 200-day moving average of $114.60.
Analyzing Johnson & Johnson’s Recent Stock Performance
Johnson & Johnson (JNJ) was trading at $114.90 on October 20, 2016, with a 50-day moving average of $118.40 and a 200-day moving average of $117.60.
TMO Focused on Strengthening Its Emerging Market Presence
Thermo Fisher Scientific (TMO) has grown in double digits in China, which is now the company’s second-largest market by geography.
Thermo Fisher Scientific’s Key Growth Strategy
Thermo Fisher Scientific reported ~$4.5 billion in revenues in 2Q16, representing YoY (year-over-year) growth of ~6%.
Noteworthy Portfolio Changes in the MFS Growth Fund
The MFS Growth Fund Class A’s assets were invested across 87 holdings as of June 2016, and it was managing assets worth $12 billion as of the end of June.
Can Thermo Fisher’s PPI Business System Continue to Drive Growth in 2016?
The PPI system has helped nourish strong top-line growth across Thermo Fisher’s businesses while boosting margins.
How Innovation Is Driving Thermo Fisher Scientific’s Growth
Thermo Fisher Scientific now has more than 800,000 products in its portfolio and has an extensive product pipeline.
How Are Thermo Fisher’s Commercial Capabilities Driving Its Share Gains?
Thermo Fisher Scientific is a leading provider of laboratory and analytical products and services. It’s a leader in the majority of its device segments.
Inside Thermo Fisher Scientific’s Emerging Markets Strategy
Thermo Fisher has a presence in more than 50 countries. It generates ~19% of its revenues from emerging markets and the rest from developed markets.
Understanding Thermo Fisher Scientific’s Financial Model
Thermo Fisher Scientific aims to deliver adjusted EPS in the range of $11.3–$12.2 by 2019. This represents a three-year CAGR of 12%–15%.
Varian Medical Systems’ Growth Potential in Radiation Oncology
Varian Medical Systems’ next big technology innovation will be high-definition radiotherapy, which is an intelligent treatment delivery system that aims to achieve 100% radiation exposure for the tumor.
What Do Analysts Recommend for Medtronic ahead of 4Q16 Results?
In a Bloomberg survey of 26 brokerage companies on May 26, 2016, about 81% of analysts rated Medtronic as a “buy,” and 19% rated it as a “hold.”
Innovation Drove Baxter’s Hospital Products Sales in 1Q16
Baxter International (BAX) reported ~$2.4 billion in total revenues in 1Q16. Of that, ~$1.5 billion was contributed by the company’s Hospital Products business.
Strong Revenue for Abbott Point of Care Diagnostics Division
Abbott Laboratories (ABT) reported $5.2 billion of revenues worldwide in 4Q15. Of that, $1.2 billion was generated through Abbott Point of Care diagnostics.
Why Abbott Laboratories Is a Leader in Nutritional Products
Abbott Laboratories’ Nutritional Products segment is the company’s leading segment, growing at a fast pace, with rapidly increasing margins and revenues.
IHI Large-Caps: Baxter Launches Mobile Health App in India
In a press release, Baxter International (BAX) announced that it has launched a new mobile app in India called Sisu Janani Seva. It’s also known as mHealth.
Behind Becton Dickinson’s Strategic Restructuring and Business Consolidation
To better position itself amid the changing medical device environment, Becton Dickinson has come to focus on restructuring and business model evolution.
How a Strong Product Portfolio Drives Thermo Fisher’s Valuations
Thermo Fisher Scientific (TMO) registered sales of $4.7 billion, representing year-over-year growth of 4% in 4Q15 and fiscal 2015 sales of ~$17 billion.
The Geographic Strategy of Thermo Fisher Scientific
Thermo Fisher Scientific is a global company, but the majority of its revenues are generated from the developed markets. The US is its largest market, generating ~48% of the company’s total revenues.
